Literature DB >> 24848865

[Heart involvement in Friedreich's ataxia].

F Weidemann1, F Scholz, C Florescu, D Liu, K Hu, S Herrmann, G Ertl, S Störk.   

Abstract

Friedreich's ataxia is a rare hereditary disease and although the gene defect has already been identified as a deficiency of the mitochondrial protein frataxin, the pathophysiology is still unknown. Although a multisystem disorder organ involvement is predominantly neurological. Besides the characteristic features of spinocerebellar ataxia the heart is frequently also affected. Cardiac involvement typically manifests as hypertrophic cardiomyopathy, which can progress to heart failure and death. So far most research has focused on the neurological aspects and cardiac involvement in Friedreich's ataxia has not been systematically investigated. Thus, a better understanding of the progression of the cardiomyopathy, cardiac complications and long-term cardiac outcome is warranted. Although no specific treatment is available general cardiac therapeutic options for cardiomyopathy should be considered. The current review focuses on clinical and diagnostic features of cardiomyopathy and discusses potential therapeutic developments for Friedreich's ataxia.

Entities:  

Mesh:

Year:  2014        PMID: 24848865     DOI: 10.1007/s00059-014-4097-y

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  32 in total

Review 1.  Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?

Authors:  D R Richardson
Journal:  Expert Opin Investig Drugs       Date:  2003-02       Impact factor: 6.206

Review 2.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

3.  Study of fatal cases of Friedreich's ataxia.

Authors:  R L Hewer
Journal:  Br Med J       Date:  1968-09-14

Review 4.  Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord.

Authors:  Arnulf H Koeppen
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

5.  Cardiac transplantation: a temporary solution for Friedreich's ataxia-induced dilated cardiomyopathy.

Authors:  Tara Leanne Sedlak; Mann Chandavimol; Lynn Straatman
Journal:  J Heart Lung Transplant       Date:  2004-11       Impact factor: 10.247

Review 6.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

Review 7.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

8.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

9.  Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI.

Authors:  Chris Meyer; Gebhard Schmid; Sabine Görlitz; Monika Ernst; Christian Wilkens; Inga Wilhelms; Peter H Kraus; Peter Bauer; Jürgen Tomiuk; Horst Przuntek; Andreas Mügge; Ludger Schöls
Journal:  Mov Disord       Date:  2007-08-15       Impact factor: 10.338

10.  Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants.

Authors:  Matthias L Jauslin; Thomas Meier; Robin A J Smith; Michael P Murphy
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

View more
  1 in total

Review 1.  Heart disease in Friedreich's ataxia.

Authors:  Emily Hanson; Mark Sheldon; Brenda Pacheco; Mohammed Alkubeysi; Veena Raizada
Journal:  World J Cardiol       Date:  2019-01-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.